Filtered By:
Condition: Stroke
Management: Medicare
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 992 results found since Jan 2013.
FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages.
Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval.
“For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research
Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation
CONCLUSIONS: Older adults with cancer and atrial fibrillation exposed to DOACs had similar risks of stroke and systemic embolism and major bleeding as those exposed to warfarin. Relative to warfarin, DOAC use was associated with a similar risk of cardiovascular death and a lower risk of all-cause death.PMID:36453260 | DOI:10.1161/CIRCOUTCOMES.122.008951
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Hemalkumar B Mehta Huijun An Shirin Ardeshirrouhanifard Mukaila A Raji G Caleb Alexander Jodi B Segal Source Type: research
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
CONCLUSIONS: Over 12 months after initiation, apixaban and dabigatran conferred progressive increases in event free time for stroke/SE and MB vs warfarin, whereas rivaroxaban conferred an increase in stroke/SE-free time but a loss in MB-free time vs warfarin.PMID:36456387 | DOI:10.1016/j.ejim.2022.10.021
Source: European Journal of Internal Medicine - December 1, 2022 Category: Internal Medicine Authors: Steven Deitelzweig Allison Keshishian Amiee Kang Aaron Jenkins Nipun Atreja Patricia Schuler Jenny Jiang Huseyin Yuce Xiaoxi Sun Gregory Y H Lip Source Type: research
As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research
Outcomes after Discharge from Inpatient Rehabilitation or Skilled Nursing in Patients Post-Stroke with Medicare Advantage
Determine differences in outcomes (functional, readmission, and community discharge) after placement in an Inpatient Rehabilitation Facility (IRF) or Skilled Nursing Facility (SNF) for patients post-ischemic stroke who have a Medicare Advantage (MA) plan.
Source: Archives of Physical Medicine and Rehabilitation - December 1, 2022 Category: Rehabilitation Authors: Heather Hayes, Christine McDonough Tags: Research Poster 2184325 Source Type: research
Association between cervical artery dissection and spinal manipulative therapy –a medicare claims analysis
Cervical artery dissection and subsequent ischemic stroke is the most serious safety concern associated with cervical spinal manipulation.
Source: BMC Geriatrics - November 29, 2022 Category: Geriatrics Authors: James M Whedon, Curtis L Petersen, Zhongze Li, William J Schoelkopf, Scott Haldeman, Todd A MacKenzie and Jon D Lurie Tags: Research Source Type: research
Ambulatory Care Fragmentation, Emergency Department Visits, and Race: a Nationwide Cohort Study in the U.S.
ConclusionsHighly fragmented ambulatory care was an independent predictor of ED visits, especially among Black individuals.
Source: Journal of General Internal Medicine - November 23, 2022 Category: Internal Medicine Source Type: research
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Hospital Closures Pose Challenges to Care
Empty beds in a hospital room.
When 10-bed Nye Regional Medical Center, in west-central Nevada, closed abruptly in 2015, it meant that the residents of the former gold-mining town of Tonopah would have to drive about two hours across a hundred miles of desert roads to get to the nearest hospital.
The hospital’s CEO, Wayne Allen, didn’t sugar-coat it.
“This is a decision that will ultimately jeopardize the health and well-being of our community and surrounding areas,” he said.
Hospital closures over the last decade—most notably in rural areas and in pediatrics, but urban closures as well—have left patients wi...
Source: The Hospitalist - November 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Business of Medicine Career Pediatrics PHM22 Source Type: research
Associations between long-term air pollution exposure and the incidence of cardiovascular diseases among American older adults
CONCLUSIONS: Long-term exposure to PM2.5, NO2, and warm-season O3 were associated with increased incidence of cardiovascular diseases, even at low pollutant concentration levels. Black people and people with diabetes were found to be vulnerable populations.PMID:36283157 | DOI:10.1016/j.envint.2022.107594
Source: Environment International - October 25, 2022 Category: Environmental Health Authors: Tingfan Jin Qian Di Weeberb J R équia Mahdieh Danesh Yazdi Edgar Castro Tszshan Ma Yifan Wang Haisu Zhang Liuhua Shi Joel Schwartz Source Type: research
Evaluation of the Million Hearts ® Cardiovascular Disease Risk Reduction Model
In this model, CMS pays participating organizations for assessing each of their eligible Medicare beneficiary ' s risk of having a heart attack or stroke over the next 10 years and for reducing CVD risk among high-risk beneficiaries.
Source: RAND Research Health and Health Care - October 25, 2022 Category: Health Management Authors: Greg Peterson; Alli Steiner; Rhea Powell; Julia Rollison; Amanda Markovitz; Laura Blue; Kate Stewart; Dan Kinber; Rachel Kogan; Danielle Whicher; Rui Wang; Jia Pu; Keith Kranker; Malcolm V. Williams; Nancy McCall; Alex Bryce; Liisa Hiatt; Elizabeth H Source Type: research
